Put May 22nd on your calendars folks

Quote

Anonymous

Guest
HRS is going to be boring somewhat as outside of the BSX sub cu ICD and all the debates about leads? yawn.................

May 22nd?

This is when the big boys are going to see what the third generation BIO stent does. I have a feeling, there may be some rather concerned folks in santa rosa, Minneapolis, Boston, and Temecula/Santa clara come May 23rd as if you see the names on this Bio flyer, some big names in Europe.

http://www.biotronik.com/files/A68476125D7CAFF5C1257B3A0043CDA4/$FILE/Scientific_Flyer.pdf
 






Anonymous said:
HRS is going to be boring somewhat as outside of the BSX sub cu ICD and all the debates about leads? yawn.................

May 22nd?

This is when the big boys are going to see what the third generation BIO stent does. I have a feeling, there may be some rather concerned folks in santa rosa, Minneapolis, Boston, and Temecula/Santa clara come May 23rd as if you see the names on this Bio flyer, some big names in Europe.

http://www.biotronik.com/files/A68476125D7CAFF5C1257B3A0043CDA4/$FILE/Scientific_Flyer.pdf
Click to expand...

Really? Who cares? Just the # of people who view this site on BIO speaks for itself. Maybe 2 people at any given time view CP....no one cares. You guys believe your own hype no one else does.
 
















































hello! from the EURO PCR this week........ Get used to the word non inferiority as not one bioabsorable is going to beat current rates of restenosis for DES

BIOFLOW-II
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angio - graphic endpoint of in-stent late lumen loss at nine months in the results of the imaging substudy BIOFLOW-II. The substudy used IVUS and optical coherence tomography (OCT) to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery disease due to de novo stenotic lesions. Patients were randomly assigned to receive either the Orsiro (Biotronik) or the Xience Prime stent (Abbott Vascular).

Results presented by Stephan Windecker showed no difference in the angiographic endpoint of instent late lumen loss between the two stents at nine months (0.10±0.32mm with the Orsiro stent vs. 0.11±0.29mm with the Xience Prime stent, p non-inferiority≤0.0001). Rates of target lesion failure were also similar at nine months (4.8% vs. 5.3%, p=0.47). The IVUS substudy showed somewhat less neointimal hyperplasia over nine months with the Orsiro stent (0.16) than the Xience stent (0.43, p=0.043) with 100% stent apposition. Similarly, neointimal area as assessed by OCT at nine months was somewhat less with the Orsiro stent (0.74±0.38mm2) than with the Xience stent (1.00±0.44mm2, p=0.024). The proportion of wellapposed struts was similar with the two stents and the proportion of covered struts was slightly higher with the Orsiro stent (98.3% vs. 97.5%, p=0.042).
 






Anonymous said:
hello! from the EURO PCR this week........ Get used to the word non inferiority as not one bioabsorable is going to beat current rates of restenosis for DES

BIOFLOW-II
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angio - graphic endpoint of in-stent late lumen loss at nine months in the results of the imaging substudy BIOFLOW-II. The substudy used IVUS and optical coherence tomography (OCT) to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery disease due to de novo stenotic lesions. Patients were randomly assigned to receive either the Orsiro (Biotronik) or the Xience Prime stent (Abbott Vascular).

Results presented by Stephan Windecker showed no difference in the angiographic endpoint of instent late lumen loss between the two stents at nine months (0.10±0.32mm with the Orsiro stent vs. 0.11±0.29mm with the Xience Prime stent, p non-inferiority≤0.0001). Rates of target lesion failure were also similar at nine months (4.8% vs. 5.3%, p=0.47). The IVUS substudy showed somewhat less neointimal hyperplasia over nine months with the Orsiro stent (0.16) than the Xience stent (0.43, p=0.043) with 100% stent apposition. Similarly, neointimal area as assessed by OCT at nine months was somewhat less with the Orsiro stent (0.74±0.38mm2) than with the Xience stent (1.00±0.44mm2, p=0.024). The proportion of wellapposed struts was similar with the two stents and the proportion of covered struts was slightly higher with the Orsiro stent (98.3% vs. 97.5%, p=0.042).
Click to expand...

WOW! Non inferior!! Great work for the past 12-15 years.....pat yourselves on the back
 






So, abbott and Boston Bioabsorbs are going to try and show "superiority" to 5% reclose rates that Xience and others have?

I dont think so.....................

You will see "non inferior" on almost every Stent trial moving forward.

Bottom line? Biotroniks sirlolimus bioabsorb can hang with anyone. My my.................... keep dissing us though, we are going to grow like crazy from 2014-18 while all the talking heads at the big three oversell their non CRM pipelines.
 






Anonymous said:
WOW! Non inferior!! Great work for the past 12-15 years.....pat yourselves on the back
Click to expand...

Now, now...I will admit, I wish our product had outperformed, but the great news is that this is only one factor that goes in to selling a stent. If it performs the same and is just as deliverable, I am sure our (BIO's) pricepoint is going to be the deciding factor in the Obamacare World.
 






Worst case scenario? Biotronik captures 20-25% of the US and global stent market. Lets assume it gets a premium price vs todays prices. If it gets a 10-15% bump over current DES prices? be in the $1700- $1800 per stent range...............

That's about 1.3 10 1.5 billion that Bio laps up in annual stent sales. I think our friends in Berlin could live with that.

DES balloon is making waves too
 






Will deliver in a like fashion to today's DES stents due to the alloy used. Issue Abbott is going to have with its BVS? their BVs is not flexible at all and tough to see, very tough.
 






Anonymous said:
Worst case scenario? Biotronik captures 20-25% of the US and global stent market. Lets assume it gets a premium price vs todays prices. If it gets a 10-15% bump over current DES prices? be in the $1700- $1800 per stent range...............

That's about 1.3 10 1.5 billion that Bio laps up in annual stent sales. I think our friends in Berlin could live with that.

DES balloon is making waves too
Click to expand...

Their delusional state never ceases to amaze me! 40 years in the US CRM market, 3% market share, 15-20 years late to market with steroid eluting leads, rate response pacers, Icds, CRTs etc etc. but now we're gonna score. The most delusional statement of all? "our 'friends' in Berlin".
Rest assured they hate Americans, and will do the opposite of what's needed to advance Bio in this market...But they do like the high price they charge the 'independent' company in Portland for product, so they can scurry off the Germany with the profits, without paying taxes in the US....how many times have you heard, we can't sell it here for such a low cost, that's more than less than we pay for it...
 






Max jr is in Switzerland not Berlin. He has been dangling that stent for years. At the Lumax 300 launch e said it will come to the states if I want it to. But I guarantee, it won't be you dinosaurs selling it.
 






Anonymous said:
Worst case scenario? Biotronik captures 20-25% of the US and global stent market. Lets assume it gets a premium price vs todays prices. If it gets a 10-15% bump over current DES prices? be in the $1700- $1800 per stent range...............

That's about 1.3 10 1.5 billion that Bio laps up in annual stent sales. I think our friends in Berlin could live with that.

DES balloon is making waves too
Click to expand...

Lot of assumptions, here, Buster. Do not bet on any price premiums. Also, remember that any longer-term performance data will always be a trump card for the DES that has been on the market the LONGEST. Bottom line: later to market and you must expect lower market share and you must offer lower market price, not what you whimsically describe above.
 






Anonymous said:
Lot of assumptions, here, Buster. Do not bet on any price premiums. Also, remember that any longer-term performance data will always be a trump card for the DES that has been on the market the LONGEST. Bottom line: later to market and you must expect lower market share and you must offer lower market price, not what you whimsically describe above.
Click to expand...

BIO will not survive on this planet. Just listen to the lack of logic in their threads. Zero industry understanding. Good luck on Mars boys.
 






Anonymous said:
BIO will not survive on this planet. Just listen to the lack of logic in their threads. Zero industry understanding. Good luck on Mars boys.
Click to expand...

Speaking of survival....when's the next RIFF scheduled? Its you who sounds 'tone deaf' regarding the current status of things in CRM.

I do disagree with the previous post suggesting we (BIO) can expect premiums for our stents...our strength will always be the ability to out-price the rest of you guys. Omar has a few more rounds of layoffs to go before you can compete in that department.

Regardless of what company you work for - if you can make a living in your TERRITORY, all this chest-thumping about how things are going COMPANY WIDE don't matter that much at the end of the day. As long as I can pay my bills - I am happy. The fact that I am doing it with BIO just adds a little pride in there....since everyone says it can't be done ethically or consistently.
 






Top Bottom
Back
Quote